fluoropharma medical inc (FPMI) Key Developments
FluoroPharma Medical, Inc. and The General Hospital Corporation Entered into Two License Agreements
Jul 1 14
On June 26, 2014, FluoroPharma Medical, Inc. and The General Hospital Corporation, d/b/a Massachusetts General Hospital (MGH) entered into two license agreements which Agreements replace the single license agreement between the Company and MGH dated April 27, 2009, as amended by letter dated June 21, 2011 and agreement dated October 31, 2011. The Agreements provide exclusive licenses for two lead product candidates, BFPET and CardioPET, two of the three cardiac imaging technologies covered by the Original Agreement. The Company and MGH are in discussions regarding the exclusive license to VasoPET, the third product candidate covered by the Original Agreement, rights to which ceased upon the termination of the Original Agreement contemporaneously with the execution of the new Agreements. The Agreements were entered into primarily for the purpose of separating the Company's rights and obligations with respect to its different product development programs. Each of the Agreements requires to pay MGH an initial license fee of $175,000 and annual license maintenance fees aggregating $250,000. The Agreements require to meet certain obligations, including, but not limited to, meeting certain development milestones relating to clinical trials and filings with the United States Food and Drug Administration.
Fluoropharma Medical, Inc. Presents Data from Phase II Clinical Trial of 18F FCPHA
May 29 14
FluoroPharma Medical, Inc. announced that data and analysis from a feasibility study on the quantification of myocardial perfusion in humans by PET/CT utilizing the fatty acid analogue (18) F-FCPHA at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting.
FluoroPharma Medical, Inc. Presents at 15th Annual B. Riley & Co. Investor Conference, May-19-2014 04:00 PM
May 12 14
FluoroPharma Medical, Inc. Presents at 15th Annual B. Riley & Co. Investor Conference, May-19-2014 04:00 PM. Venue: Loews Santa Monica Beach Hotel, 1700 Ocean Avenue, Santa Monica, CA 90401, United States. Speakers: Johan M. Spoor, Chairman, Chief Executive Officer and President.
FluoroPharma Medical, Inc. Presents at LD MICRO 4th Annual Micro-Cap Invitational, Jun-04-2014 09:00 AM
May 7 14
FluoroPharma Medical, Inc. Presents at LD MICRO 4th Annual Micro-Cap Invitational, Jun-04-2014 09:00 AM. Venue: Luxe Sunset Bel Air, 11461 Sunset Boulevard, Los Angeles, CA 90049, United States.
FluoroPharma Medical, Inc. Appoints H. William Strauss to Chair the Scientific Advisory Board
Apr 14 14
FluoroPharma Medical, Inc. announced that Dr. H. William Strauss has been appointed to chair the company's scientific advisory board. Dr. Strauss currently serves as an Attending Physician Emeritus of the Molecular Imaging and Therapy Nuclear Medicine Service at Memorial Sloan Kettering Cancer Center & Memorial Hospital in New York City. He joined the Memorial Sloan Kettering/Cornell faculty and staff in 2001, following 30 years of faculty, clinical and research appointments in radiology at the medical schools and teaching hospitals of Johns Hopkins, Harvard, Stanford and Cornell University medical centers. For two years in the early 1990s, he also served as Vice President-Diagnostics Drug Discovery for Bristol-Myers Squibb Co.